Skip to content

A clinical study evaluating the effect of disulfiram on the diversity and structure of gut microbiota in healthy volunteers

A clinical study evaluating the effect of disulfiram on the diversity and structure of gut microbiota in healthy volunteers

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048035
Enrollment
Unknown
Registered
2021-06-28
Start date
2021-07-30
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteer

Interventions

Case series:Disulfiram oral, 250 mg daily after dinner

Sponsors

Department of Gastroenterology, Second Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Take 33 healthy people who volunteered to participate in the study in the Second Affiliated Hospital of the Army Military Medical University as the source of the research objects.

Exclusion criteria

Exclusion criteria: 1. People suffering from alcoholic fatty liver disease; 2. Those suffering from severe renal dysfunction; 3. According to the judgment of the investigator, there is a clinically significant medical condition that may affect research participation and/or personal health, including but not limited to the following conditions: (1) Medical history of cardiovascular and cerebrovascular disease events in the past 6 months; (2) Anticoagulant therapy is needed; (3) Gastrointestinal diseases include but are not limited to the following diseases: pancreatitis, inflammatory bowel disease or other diseases related to malabsorption or persistent abdominal discomfort; (4) Endocrine diseases other than type 2 diabetes and hypothyroidism; (5) Chronic infection (for example, tuberculosis, HIV infection, hepatitis A virus, hepatitis B virus or hepatitis C virus); (6) Neurological or mental diseases that hinder the effective implementation of informed consent or may interfere with the subject's compliance with the research procedures (for example, severe depression in the last 2 years, suicidal behavior in the last 3 months); (7) Medical history of other mental illnesses, including schizophrenia and bipolar disorder; 4. Those who have recently taken multiple drugs for the treatment of diseases, such as: (1) Metronidazole, isoniazid, theophylline, tinidazole; (2) Seizure drugs: such as phenytoin (dilantine); (3) Blood thinning drugs (including warfarin, coumarin, Yantofen), isoniazid, etc.); 5. Those who have recently consumed any alcohol-containing food or used alcohol-containing products (such as mouthwash, cough suppressant, cooking wine, certain desserts, colognes, perfume, antiperspirants, antiseptic astringent skin products, hair dyes, etc.). 6. Those who are pregnant or breastfeeding; 7. Participated in a weight loss plan within the past 3 months; 8. Weight change in the past month =5%; 9. Donated blood within 3 months before screening, or plan to donate blood during the study period; 10. Those who have not signed the informed consent and or the research process has not been completed.

Design outcomes

Primary

MeasureTime frame
Diversity and structure of gut microbiota;Key metabolites of gut microbiota;

Countries

China

Contacts

Public ContactYang Shiming

The Second Affiliated Hospital of Army Medical University

13228686589@163.com+86 13228686589

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026